Ovarian, endometrial, and colorectal cancers

Obstetrics and Gynecology

Volumn 104, Issue 4 SUPPL., 2004, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

COLORECTAL TUMOR; ENDOMETRIUM TUMOR; ESTROGEN THERAPY; FEMALE; HUMAN; OVARY TUMOR; PRACTICE GUIDELINE; REVIEW;

COLORECTAL NEOPLASMS; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OVARIAN NEOPLASMS; PRACTICE GUIDELINES;

EID: 16544377165     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000138797.20914.34     Document Type: Article

References (61)

1. American Cancer Society. Cancer facts & figures: 2003. Atlanta (GA): ACS; 2003. (Level II-3)
2. Piver MS, Baker TR Jishi MF, Sandecki AM, Tsukada Y, Natarajan N, et al. Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 1993; 71(suppl): 582-8. (Level II-2) (Pubitemid 23021254)
3. U. S. Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002; 137: 834-9. (Level III)
4. Garg PP, Kerlikowske K, Subak L., Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998; 92: 472-9. (Meta-analysis) (Pubitemid 28396879)
5. Anderson GL, Judd HL, Kaunitz A.M., Barad DH, Beres ford SA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1739-48. (Level I) (Pubitemid 37430624)
6. Coughlin SS, Giustozzi A, Smith S.J., Lee NC A metaanalysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000; 53: 367-75. (Meta-analysis) (Pubitemid 30216475)
7. Lacey JVJr, Mink PJ, Lubin J.H., Sherman ME, Troisi R, Hartge P, et al Menopausal hormone replacement therapy and risk of ovarian cancer [published erratum appears in JAMA 2002; 288: 2544]. JAMA 2002; 288: 334-41. (Level II-2) (Pubitemid 34761612)
8. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002; 94: 497-504. (Level II-2) (Pubitemid 34411288)
9. Purdie DM, Bain CJ, Siskind V, Russell P., Hacker NF, Ward BG, et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 1999; 81: 559-63. (Level II-2) (Pubitemid 29458815)
10. Sit AS, Modugno F, Weissfeld J.L., Berga SL, Ness RB Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 2002; 86: 118-23. (Level II-2) (Pubitemid 34953491)
11. Rodriguez C, Patel AV, Calle E.E., Jacob EJ, Thun MJ Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285: 1460-5. (Level II-2) (Pubitemid 32221894)
12. Riman T, Dickman PW, Nilsson S, Correia N., Nordlinder H, Magnusson CM, et al Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 2001; 83: 575-85. (Level II-2) (Pubitemid 33139723)
13. Rebbeck TR, Levin AM, Eisen A, Snyder C., Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91: 1475-9. (Level II-2) (Pubitemid 29424552)
14. Meiser B, Tiller K, Gleeson M.A., Andrews L., Robertson G, Tucker KM Psychological impact of prophylactic oophorectomy in women at increased risk for ovarian cancer. Psychooncology 2000; 9: 496-503. (Level III) (Pubitemid 32010922)
15. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 1999; 86: 1013-8. (Level I) (Pubitemid 29439856)
16. Ursic-Vrscaj M., Bebar S, Zakelj MP Hormone replacement therapy after invasive ovarian serous cystadenocar-cinoma treatment: the effect onsurvival. Menopause 2001; 8: 70-5. (Level II-2) (Pubitemid 32066583)
17. Watson P, Vasen HF, Mecklin J.P., Jarvinen H., Lynch HT The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96: 516-20. (Level II-2) (Pubitemid 24184436)
18. Grady D, Gebretsadik T, Kerlikowske K., Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304-13. (Meta-analysis)
19. Hammond CB, Jelovsek FR, Lee K.L., Creasman WT, Parker RT Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol 1979; 133: 537-47. (Level II-2) (Pubitemid 9110981)
20. Gambrell RD Jr., Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980; 55: 732-8. (Level II-2) (Pubitemid 10068686)
21. Persson I, Adami HO, Bergkvist L, Lindgren A., Pettersson B, Hoover R, et al Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298: 147-51. (Level II-2) (Pubitemid 19039672)
22. Rossouw JE, Anderson GL, Prentice R.L., LaCroix AZ, Kooperberg C, Stefanick ML, et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33. (Level I) (Pubitemid 34761611)
23. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The Postmeno-pausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996; 275: 370-5. (Level I)
24. Pickar JH, Yeh I, Wheeler J.E., Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 76: 25-31. (Level I) (Pubitemid 32600955)
25. Speroff L, Rowan J, Symons J., Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study): a randomized controlled trial. JAMA 1996; 276: 1397-403. (Level I) (Pubitemid 26365845)
26. Hulley S, Furberg C, Barrett-Connor E, Cauley J., Grady D, Haskell W, et al Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66. (Level I) (Pubitemid 34705519)
27. Whitehead MI, King RJ, McQueen J, Campbell S. Endo-metrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestogen therapy. J R Soc Med 1979; 72: 322-7. (Level II-3) (Pubitemid 9189524)
28. Studd JW, Thom MH, Paterson M.E., Wade-Evans T. The prevention and treatment of endometrial pathology in post-menopausal women receiving exogenous estrogens. In: Pasetto N, Paoletti R, Ambrus JL, editors. The menopause and postmenopause: the proceedings of an international symposium held in Rome, June 1979. Lancaster (UK): MTP Press, 1980. p. 127-39. (Level III)
29. Genant HK, Lucas J, Weiss S., Akin M, Emkey R, McNaney-Flint H, et al. Low-dose esterified estrogen therapy: effects on bone, plasma E2 concentrations, endome-trium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 1997; 157: 2609-15. (Level I) (Pubitemid 27519981)
30. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder T., Lane G, Siddle N, et al Actions of progestins on the morphology and biochemistry of the endometrium of postmenopausal women receiving low-dose estrogen therapy. Am J Obstet Gynecol 1982; 142: 791-5. (Level II-3) (Pubitemid 12135904)
31. Kurman RJ, Felix JC, Archer D.F., Nanavati N., Arce J, Moyer DL Norethindrone acetate and E2-induced endo-metrial hyperplasia. Obstet Gynecol 2000; 96: 373-9. (Level I)
32. Enriori CL, Reforzo-Membrives J. Peripheral aromatization as a risk factor for breast and endometrial cancer in postmenopausal women: a review. Gynecol Oncol 1984; 17: 1-21. (Level III) (Pubitemid 14176287)
33. Zeleniuch-Jacquotte A., Akhmedkhanov A, Kato I., Koenig KL, Shore RE, Kim MY, et al Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001; 84: 975-81. (Level II-2) (Pubitemid 32385843)
34. Davidson BJ, Gambone JC, Lagasse L.D., Castaldo TW, Hammond GL, Siiteri PK, et al Free E2 in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab 1981; 52: 404-8. (Level II-2) (Pubitemid 11136547)
35. Bergstrom A, Pisani P, Tenet V., Wolk A, Adami HO Overweight as an avoidable cause of cancer in Europe [published erratum appears in Int J Cancer 2001; 92: 927]. Int J Cancer 2001; 91: 421-30. (Meta-analysis) (Pubitemid 32049639)
36. Troisi R, Potischman N, Hoover R.N., Siiteri P., Brinton LA Insulin and endometrial cancer. AmJ Epidemiol 1997; 146: 476-82. (Level II-2) (Pubitemid 27391408)
37. Fornander T, Rutqvist LE, Cedermark B, Glas U., Mattsson A, Silfversward C, et al Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117-20. (Level I) (Pubitemid 19034031)
38. Rutqvist LE, Johansson H, Signomklao T., Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995; 87: 645-51. (Level I)
39. Fisher B, Costantino JP, Wickerham D.L., Redmond CK, Kavanah M, Cronin WM, et al Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P1 Study. J Natl Cancer Inst 1998; 90: 1371-88. (Level I) (Pubitemid 28439961)
40. Creasman WT, Henderson D, Hinshaw W., Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986; 67: 326-30. (Level II-2) (Pubitemid 16129969)
41. Lee RB, Burke TW, Park RC Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990; 36: 189-91. (Level II-2) (Pubitemid 20061284)
42. Chapman JA, DiSaia PJ, Osann K, Roth P.D., Gillotte DL, Berman ML Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996; 175: 1195-200. (Level II-2) (Pubitemid 26398977)
43. Ries LAG, Eisner MP, Kosary C.L., Hankey BF, Miller BA, Clegg L, et al SEER cancer statistics review, 1975-2000. Bethesda (MD): National Cancer Institute; 2003. Available at: http://seer.cancer.gov/csr/1975-2000/. Retrieved December 9, 2003. (Level II-3)
44. Grodstein F, Newcomb PA, Stampfer MJ Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. AmJ Med 1999; 106: 574-82. (Meta-analysis) (Pubitemid 29231110)
45. Nanda K, Bastian LA, Hasselblad V, Simel DL Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999; 93: 880-8. (Metaanalysis) (Pubitemid 29197937)
46. Hebert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev 1998; 7: 653-9. (Meta-analysis) (Pubitemid 28374594)
47. MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies. MedJAust 1995; 162: 491-3. (Meta-analysis)
48. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C., Hubbell FA, Ascensao J, Rodabough RJ, et al Estrogen plus progestin and colorectal cancer in postmenopausal women: Women's Health Initiative Investigators. N Engl J Med 2004; 350: 991-1004. (Level I) (Pubitemid 38269276)
49. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12. (Level I)
50. Prihartono N, Palmer JR, Louik C, Shapiro S., Rosenberg L. A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 443-7. (Level II-2) (Pubitemid 30265790)
51. Newcomb PA, Taylor JO, Trentham-Dietz A. Interactions of familial and hormonal risk factors for large bowel cancer in women. Int J Epidemiol 1999; 28: 603-8. (Level II-2) (Pubitemid 29401315)
52. Persson I, Yuen J, Bergkvist L., Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327-32. (Level II-2) (Pubitemid 26274121)
53. Calle EE, Miracle-McMahill HL, Thun M.J., Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995; 87: 517-23. (Level II-2)
54. Sturgeon SR, Schairer C, Brinton L.A., Pearson T., Hoover RN Evidence of a healthy estrogen user survivor effect. Epidemiology 1995; 6: 227-31. (Level II-2)
55. Newcomb PA, Storer BE Postmenopausal hormone use and risk of large-bowel cancer [published erratum appears in J Natl Cancer Inst 1995; 87: 1416]. J Natl Cancer Inst 1995; 87: 1067-71. (Level II-2)
56. Troisi R, Schairer C, Chow W.H., Schatzkin A., Brinton LA, Fraumeni JF Jr. A prospective study of menopausal hormones and risk of colorectal cancer (United States). Cancer Causes Control 1997; 8: 130-8. (Level II-2) (Pubitemid 27170367)
57. Fiorelli G, Picariello L, Martineti V., Tonelli F, Brandi ML Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol 1999; 71: 223-30. (Level II-2) (Pubitemid 30125685)
58. Lointier P, Meggouh F, Pezet D., Dapoigny M, Dieng PN, Saez S, et al Specific receptors for 1, 25-dihydroxyvitamin D3 (1, 25-DR) and human colorectal carcinogenesis. Anticancer Res 1989; 9: 1921-4. (Level III) (Pubitemid 20082189)
59. Lointier P, Wildrick DM, Boman BM The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer Res 1992; 12: 1327-30. (Level III)
60. Al-Azzawi F., Wahab M. Estrogen and colon cancer: current issues. Climacteric 2002; 5: 3-14. (Level III) (Pubitemid 34309851)
61. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7: 536-40. (Level III) (Pubitemid 24308343)